In previously proposed legislation, the HHS nominee sought to grant physician groups final say over quality measures and comparative-effectiveness research.
The heads of the CMS and the Food and Drug Administration want universal health insurance claims forms to include unique device identifiers. The UDI would improve post-market surveillance and provide for better value-based reimbursement based on device performance, they say.
Are the drugs excluded from formularies by pharmacy benefits managers really no better than what's available at a cheaper price?
Health systems and hospitals that are taking financial risk for keeping people healthy aren't the only ones that want access to patient-generated data. Drug and biotech firms know patient-reported information can help get their products to market faster and assess how they perform in the real world.
The drug and medical device industries are not immune to the healthcare industry’s transition from volume to value.
The drug and medical industries have not been immune from the healthcare industry's transition from volume to value.
Physicians have increasingly looked to 3-D printing for unique implants and surgical models, and some manufacturers are now using the method to mass produce medical devices and even drugs that are more precise, customizable and biocompatible than conventionally produced products.
The Food and Drug Administration is recommending that biosimilar labels carry the clinical data gathered by the product the biosimilar is intended to emulate. Biosimilars are derived from living organisms, and therefore may not be identical to brand-name drugs.
The CMS' decision this week to pay for the Diabetes Prevention Program is long overdue since its success in reducing obesity and thereby diabetes risk has been well documented in the medical and healthcare economics literature, and covered by certain sections of the press—like us.
I read with interest the article “In California, where moms deliver affects whether they have a C-section." As a private-practice OB-GYN for the past 23 years working mostly in a community hospital, the numbers showing high variability in the state certainly raise the question, who is...
For more than a year, top officials from Medicare, the nation's largest health plans, medical societies and major employers and consumer groups hammered away at a dreadful task: getting everyone to agree to use identical quality measures for the treatment of heart disease, cancer and other common...